KRAS and neoplasm: The discovery of the switch II pocket within the KRAS protein has rapidly accelerated the development of KRASG12C inhibitors, such as sotorasib, adagrasib, divarasib, garsorasib (D-1553), and D3S-001.18 IBI351, as a novel, irreversible covalent KRASG12C inhibitor, has demonstrated promising anti-tumour activity in patients with advanced solid tumours.16 This report, based on pooled data from the phase I part of two studies, aims to evaluate the efficacy and safety of IBI351 monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic CRC.